Registry Platform Ovarian and Endometrial Cancer

Launched by IOMEDICO AG · Nov 10, 2021

Keywords

ClinConnect Summary

This clinical trial is focused on understanding and tracking the experiences of women with advanced ovarian cancer and advanced endometrial cancer. Researchers are setting up a national registry to collect important information about the disease, treatments, and how patients feel throughout their journey. This study aims to gather consistent data from multiple centers across Germany, which will help improve future treatments and care for these cancers.

To participate, women aged 65 to 74 with specific types of advanced ovarian or endometrial cancer may be eligible. Key criteria include having high-grade ovarian cancer at an advanced stage or advanced endometrial cancer starting new treatment. Participants will be asked to provide consent to join and can expect to share their experiences and outcomes during the course of the study. This trial is currently recruiting, and it offers a chance to contribute valuable information that could benefit future patients facing similar challenges.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• * Confirmed high grade OC (advanced or metastatic epithelial ovarian, fallopian tube and primary peritoneal cancer):
• • patients with FIGO stage IIb-IV OC who are starting systemic treatment or
• • patients with recurrent/relapsed disease, who received any previous systemic anti-tumor treatment and who are now starting systemic treatment for recurrent/relapsed disease.
• • Locally advanced and inoperable or metastatic EC (FIGO stage III-IV) who are starting systemic first-line therapy.
• * Signed and dated informed consent (IC):
• • Patients participating in PRO module: IC before first therapy cycle
• • Patients not participating in PRO module: IC no later than six weeks after start of first therapy cycle
• Exclusion Criteria:
• • newly diagnosed early-stage OC (FIGO stage I-IIa)
• • Low grade mOC OR
• • Early-stage EC (FIGO stage I-II)